Lilly’s Zepbound will first be given in the UK to those with ‘highest clinical need’

Given the strong demand expected for Eli Lilly’s (NYSE:LLY) weight loss treatment Zepbound (tirzepatide) in the UK, the country’s National Institute for Health and Care Excellence (“NICE”) said the drug will first be offered to people with the “highest clinical need.”